Cellular and molecular pathogenesis of systemic lupus erythematosus: lessons from animal models

Systemic lupus erythematosus (SLE) is a complex disease characterized by the appearance of autoantibodies against nuclear antigens and the involvement of multiple organ systems, including the kidneys. The precise immunological events that trigger the onset of clinical manifestations of SLE are not yet well understood. However, research using various mouse strains of spontaneous and inducible lupus in the last two decades has provided insights into the role of the immune system in the pathogenesis of this disease. According to our present understanding, the immunological defects resulting in the development of SLE can be categorized into two phases: (a) systemic autoimmunity resulting in increased serum antinuclear and antiglomerular autoantibodies and (b) immunological events that occur within the target organ and result in end organ damage. Aberrations in the innate as well as adaptive arms of the immune system both play an important role in the genesis and progression of lupus. Here, we will review the present understanding - as garnered from studying mouse models - about the roles of various immune cells in lupus pathogenesis.


Introduction
Our understanding of the pathogenesis mechanisms leading to lupus has been augmented by the analysis of several diff erent murine models over the past four decades. Various mouse models of spontaneous lupus have been employed in an eff ort to understand the cellular and genetic mechanisms behind induction of systemic lupus erythematosus (SLE). Th e classic models of spontaneous lupus include the F1 hybrid of the New Zealand Black (NZB) and New Zealand White (NZW) strains, called NZB/W F1, and its derivatives, such as NZM2328 and NZM2410, and the MRL/lpr and BXSB/ Yaa strains. Th e goal of this review is to discuss the systemic and local immune responses -as learned from the studies employing various mouse model systemsthat lead to the development of lupus. Th e cellular and molecular mechanisms that contribute to the pathogenesis of lupus are discussed in the following sections and are illustrated in Figure 1.

Systemic autoimmunity in systemic lupus erythematosus: handling of self-antigens
Th e presence of high titers of autoantibodies against nuclear antigens is the hallmark of SLE. Whereas there is little evidence to indicate whether self-antigens in SLE are aberrant in sequence or structure, there is evidence that the aberrant handling of self-antigens could facilitate lupus pathogenesis. Although apoptotic bodies are normally rapidly cleared with the help of the complement and other systems, defects in this clearance system could lead to the accumulation of apoptotic bodies and their prevalence in serum [1]. Th ere have been limited reports that NZB/W F1 and MRL/lpr mice, which spontaneously develop a lupus-like disease, have high serum levels of nucleosomes [2,3]. Non-autoimmune C3H, BALB/c, and C57BL/6 mouse strains, when injected with apoptotic bodies, developed serum autoantibodies similar to those seen in SLE [4]. Although these studies warrant independent confi rmation, they support the notion that apoptotic cells could harbor the immunogens responsible for antinuclear antibody formation. Moreover, mice with defects in genes that play an important role in the clearance of apoptotic bodies, like DNase I, serum amyloid protein P (SAP), sIgM, or tyrosine kinase c-mer, all develop SLElike disease with elevated levels of anti-nuclear antibodies [5][6][7][8]. Th ese data support the hypothesis that the inefficient clearance of apoptotic bodies could be one factor leading to the development of SLE. Th e important role of the complement system and FcR in the process of clearing apoptotic materials has also been recently documented. Th us, C1q-defi cient mice exhibit impaired internali zation of apoptotic cells by peritoneal macro phages Abstract Systemic lupus erythematosus (SLE) is a complex disease characterized by the appearance of autoantibodies against nuclear antigens and the involvement of multiple organ systems, including the kidneys. The precise immunological events that trigger the onset of clinical manifestations of SLE are not yet well understood. However, research using various mouse strains of spontaneous and inducible lupus in the last two decades has provided insights into the role of the immune system in the pathogenesis of this disease. According to our present understanding, the immunological defects resulting in the development of SLE can be categorized into two phases: (a) systemic autoimmunity resulting in increased serum antinuclear and anti-glomerular autoantibodies and (b) immunological events that occur within the target organ and result in end organ damage. Aberrations in the innate as well as adaptive arms of the immune system both play an important role in the genesis and progression of lupus. Here, we will review the present understanding -as garnered from studying mouse models -about the roles of various immune cells in lupus pathogenesis. and develop proliferative glomerulonephritis characterized by high levels of apoptotic cell bodies [9].

B lymphocytes in systemic lupus erythematosus
Autoantibodies are major contributors to end organ damage as illustrated by the glomerulonephritis asso ciated with anti-nuclear and anti-glomerular antibodies, congenital heart block associated with anti-Ro antibody, and thrombosis associated with anti-cardiolipin anti bodies [10]. However, B cells can contribute to SLE patho genesis through additional pathways. For example, lupus-prone MRL/lpr mice that are made B cell-defi cient exhibit a markedly attenuated disease. Th ese mice have an absence of autoantibodies, as expected, but also display a dramatic lack in T-cell activation. Th is study, by Shlomchik and colleagues [11], implied an essential role for B cells, but not necessarily autoantibodies, in the pathogenesis of lupus [11]. In another study, Shlomchik and colleagues [12] used MRL/lpr mice expressing a mutant immunoglobulin (Ig) that cannot be secreted, thus essentially prohibiting autoantibody generation, and

Systemic Processes in Lupus
Increased self-Ag presentation of Defective phagocytosis showed that those mice still developed nephritis and vasculitis with associated T-cell activation. Th at study convincingly showed that B cells may contribute to the development of lupus in ways that are independent of autoantibodies. Th e additional role of B cells as antigenpresenting cells that mediate T-cell activation in lupus comes from MRL/lpr mice studies showing that B-cell defi ciency leads to reduced CD4 + and CD8 + T-cell activation [13].
Besides secreting proinfl ammatory cytokines like interleukin-6 (IL-6) and interferon-gamma (IFN-γ), B cells may secrete IL-10, which has an anti-infl ammatory function. Th erefore, B cells that secrete IL-10 (or B10 cells) have been called regulatory B cells and were fi rst reported in B10.PL mice in which IL-10-producing B cells were found to regulate the severity of experimental autoimmune encephalitis [14]. In murine lupus, IL-10 defi ciency was found to contribute to more severe disease with an increase in Th 1 cytokine levels [15]. A recent study using CD19 −/− NZB/W mice reported that B10 cells could induce expansion of regulatory T cells, a subset of T cells with immunosuppressive function [16]. However, data from human lupus reveal a diff erent facet of IL-10. In the case of human SLE, studies suggest that IL-10 promotes rather than inhibits lupus [17]. A better understanding of the role of IL-10-producing B cells and the mechanism of action of IL-10 is required to explain the diff erences between the murine and human data.
Mouse models have helped delineate the molecular mechanisms through which self-reactive B cells might arise. Sle1 is a lupus susceptibility locus derived from the NZM2410 mouse strain. Using Sle1 congenic C57Bl6 mice, Kumar and colleagues [18] reported that the autoimmune-associated variant of the Ly108 gene, a member of the SLAM family of immune cell receptors which lies within the Sle1 locus, leads to loss of B-cell tolerance because of impaired negative selection of autoreactive B cells at the immature B-cell stage. On the other hand, increased B-cell signaling, especially in the case of mature peripheral B cells, has been implicated in the pathogenesis of humoral autoimmunity. Mice that are defi cient in various inhibitory molecules that dampen B-cell receptor (BCR) signaling, such as SHP-1 [19], Lyn [20], or FcγRIIb [21], develop systemic autoimmunity. Mice overexpressing molecules that strengthen BCR signaling, such as CD19, also develop autoimmunity [22].
Recent studies have implicated a class of immune system receptors called Toll-like receptors (TLRs) in the synergistic activation of B cells by BCR and TLR signaling. Simultaneous engagement of BCRs that are specifi c for DNA by nuclear antigens that are abundant in apoptotic material and TLR9 on B cells causes activation of both BCR and TLR signaling pathways [23]. In the NZB/W and MRL/lpr mouse models of lupus, activation of TLR9 with a synthetic DNA ligand causes accelerated nephritis with increased anti-DNA antibody levels [24]. On the other hand, TLR9-defi cient autoimmune mouse models exhibit lower levels of anti-double-stranded DNA (anti-dsDNA) and anti-chromatin antibody [25]. Similarly, B cells possessing BCRs specifi c for RNA could be synergistically activated by BCR and TLR7 signaling [26]. Th ese fi ndings were supported by research in the BXSB mouse model of lupus. Duplication of the TLR7 gene in the Yaa lupus susceptibility locus leads to increased gene dosage eff ects that contribute to the lupus-like phenotype seen in this model [27].
Defects that may lead to increased survival of autoreactive B cells have also been found to contribute to the development of autoimmunity. B-cell activation factor (BAFF) is a major B-cell survival factor that func tions particularly at the transitional B-cell stage. BAFF transgenic mice develop a lupus-like disease with expansion of the peripheral B-cell pool and heightened production of autoantibodies [28]. Increased BAFF levels are thought to infringe the negative selection checkpoint at the T1 transitional stage, thereby allowing the survival and maturation of autoreactive B cells in the periphery and their participation in the germinal center reaction. Th ese fi ndings are supported by the observations that lupusprone mice exhibit elevated serum BAFF levels and that administration of TACI-Ig, which acts as a soluble receptor for BAFF, is eff ective in treating murine lupus [29].

T lymphocytes in systemic lupus erythematosus
Th e obligatory role of T cells in lupus pathogenesis has been demonstrated by using several genetically engi neered mouse models [30]. Lupus T cells are likely to contribute to disease through contact-dependent mechanisms (mediated by CD40L:CD40, OX40L:OX40, and so on) as well as released cytokines [30]. One important cytokine secreted by the Th 1 cells is IFN-γ, which plays a pivotal role in the production of pathogenic isotypes of antinuclear autoantibodies in murine lupus models. Expression of IFN-γ in the skin of transgenic mice leads to the production of anti-DNA and anti-Sm autoantibodies [31]. A defi ciency of IFN-γ in MRL/lpr and NZB/W lupus-prone mice leads to reduced anti-DNA antibody levels [32,33]. In support of these fi ndings, blocking the IFN-γ receptor with monoclonal antibodies or soluble IFN-γ receptor reduces disease activity in lupus-prone mice [34,35].
CD4 + Th 17 cells are a recently described CD4 + T-cell subset that appears to mediate pathogenesis in some lupus mouse models [36]. However, it has become clear that the contribution of Th 17 cells to autoimmunity is far more complex, depending on the disease and mouse model [37]. Studies in patients with SLE or related diseases have demonstrated that Th 17 cells may have a role in disease development in some, but not all, patients [38]. Given the heterogeneity of the disease, it may be possible that Th 17 cells play a role in lupus pathogenesis in a genetically defi ned subset of subjects or in particular end organ manifestations and that anti-IL-17 therapy may be helpful specifi cally in those patients. In addition, the regulatory T cell subset appears to modulate the breakdown of T-cell tolerance in lupus [39]. Clearly, we need to gain a better understanding of how pathogenic T cells (Th 17 cells) and regulatory T cells, perhaps in yinyang fashion, dictate disease activity in lupus.

Innate immune cells as mediators of systemic autoimmunity in systemic lupus erythematosus
Th e important role of the innate immune system in SLE pathogenesis has only recently been appreciated. Described below are the possible roles played by three key cell types in the innate immune system.

Monocytes/macrophages
Monocytes/macrophages from patients with lupus have been found to have a reduced capacity to phagocytose apoptotic materials [40], and their numbers were reduced in the infl ammatory exudates from patients with SLE [41]. It was postulated, on the basis of those studies, that the defective phagocytosis of monocytes/macrophages contributed to ineffi cient clearing of apoptotic materials, leading to autoimmunity [42], a notion that is supported by mice lacking the myeloid cell receptors, Tyro3, Axl, and Mer receptor tyrosine kinases [43,44]. Whereas c-mer knockout mice exhibited increased anti-dsDNA auto antibody levels without any signifi cant renal pathology [43], Tyro3/Axl/Mer triple-knockout mice exhibited high levels of autoantibodies along with multiple end organ involvement [44].
Monocytes/macrophages can contribute to disease in another important way: through the elaboration of proinfl ammatory cytokines and chemokines. Th is is illustrated by macrophages from B6.Sle3 congenic mice, in which Sle3 is a lupus susceptibility locus derived from the NZM2410 lupus-prone strain [45]. Th ese murine studies showed that monocytes/macrophages in lupus probably have defects beyond abnormal phagocytosis and that these cells may take part in aberrant regulation of the immune system. A study by Kilmon and colleagues [46] demonstrated that macrophages regulate B-cell tolerance by secreting regulatory factors like IL-6 and CD40L and that macrophages from lupus-prone MRL/lpr mice are less capable of repressing Ig secretion coincident with reduced secretion of these repressive factors. Collectively, these fi ndings implicate a more signifi cant role for monocytes/macrophages in the pathogenesis of lupus, but further studies in patients with SLE are necessary to substantiate these fi ndings.

Polymorphonuclear cells in systemic lupus erythematosus
A neutrophil-specifi c gene expression signature was reported to correlate positively with SLE disease activity in patients with SLE [47], suggesting that these cells may play an important role in SLE pathogenesis. Th e exact mechanism by which this occurs is not yet clear. However, a recent study demonstrated that neutrophil extracellular traps, which are networks of DNA, histones, and neutrophil proteins that function primarily to trap microorganisms, may be involved in SLE pathogenesis, possibly by generating autoantigens and serving as adjuvants [48]. Th e role of neutrophils in murine lupus, unlike that in human lupus, is poorly studied.

Dendritic cells in systemic lupus erythematosus
Studies in mouse models have been pivotal in deter mining the role that dendritic cells (DCs) play in the pathogenesis of lupus. One of the earliest fi ndings implicating the putative role of DCs in the breakdown of tolerance was that transferring DCs from normal donor mice to normal recipient mice could cause loss of tolerance in the host, leading to the appearance of anti-DNA and anticardiolipin autoantibodies [49]. A study by Chen and colleagues [50] showed that mice with defective DC apoptosis accumulated large numbers of DCs and exhibited chronic lymphocyte activation and systemic autoimmunity.
Other studies using murine models have helped in identifying the genetic loci responsible for imparting the abnormal phenotypes seen in DCs from lupus-prone mice. One such locus is Sle3, which is a lupus susceptibility locus derived from the NZM2410 strain of lupusprone mice. C57BL/6 (B6) mice congenic for Sle3 develop moderate glomerulonephritis along with modest levels of anti-nuclear antibodies [51]. Moreover, the DCs from B6.Sle3 congenics are less susceptible to apoptosis, have a more mature phenotype, and are more proinfl am matory. Th ey are also more effi cient in stimulating T cells in vitro and eliciting autoantibodies in vivo compared with DCs from normal B6 mice [45]. Th ese studies provided insights into genetic factors and immune mechanisms related to abnormal DC activation in murine lupus.
Studies have also shown that DCs play an important role in SLE pathogenesis by secreting potent pro infl ammatory cytokines, such as type I IFNs (IFN-α) [52]. Immune complexes (ICs) purifi ed from sera of patients with SLE were found to stimulate plasmacytoid DCs (pDCs) to produce IFN-α [53]. Later studies revealed a possible role of TLRs as potent inducers of IFN-α production by activated pDCs in lupus. IFN-α secreted by activated pDCs was found to directly infl uence B cells to produce antibodies of the IgG subclass against soluble autoantigens in mice [54]. Th is cytokine also upregulated BAFF expression by monocytes and mature DCs, which promotes both the survival of autoreactive B cells and their diff erentiation into plasmablasts [55]. Together, these reciprocal events lead to a pathogenic cycle, in which both the innate and adaptive immune systems cooperate and feedback upon each other, eventually leading to high titers of autoantibodies.

Local autoimmunity in systemic lupus erythematosus
SLE is an autoimmune disease that aff ects multiple organ systems, including the kidney, skin, heart, lung, and hematopoietic and nervous systems. As reviewed below and illustrated in Figure 1, the players mediating local autoimmunity and renal disease in lupus can be classifi ed broadly as (a) ICs and infi ltrating cells of hematological origin and (b) resident cells of the kidneys.

Role of immune complexes and infi ltrating cells of hematological origin in lupus nephritis{Level 2 heading}
Anti-DNA and DNA ICs were the fi rst ICs isolated from kidney elutes of patients with SLE and mouse models [56]. Intraperitoneal injection of human and murine anti-DNA antibodies was found to trigger lupuslike kidney disease [57], establishing a direct role of these antibodies in the pathogenesis of lupus nephritis. Similarly, transgenic overexpression of Ig anti-DNA antibodies in mouse models can lead to renal pathology similar to that seen in human lupus nephritis, highlighting a causal role for autoantibodies in the development of lupus nephritis [58].
Various mechanisms have been proposed to explain how anti-DNA antibodies may lead to renal disease in lupus [59]. Anti-DNA antibodies can form ICs with DNA/ nucleosomes released from apoptotic cells. Eventually, ICs become deposited in the kidney, leading to the initiation of a local infl ammatory response through FcγRor complement-mediated mechanisms or both. Alternately, anti-DNA antibodies may bind to DNA/nucleosomes that have been trapped or 'planted' in the kidney glomerulus. A third mechanism suggests possible crossreactivity between anti-DNA antibodies and local renal antigens like laminin, alpha-actinin, and heparan sulfate [60].
Other studies have shown that anti-DNA antibodies are not an absolute requirement for development of SLE. NZM2328.Lc4 mice exhibit lupus-like disease with glomerular IC deposits and eventually develop fatal lupus nephritis. Th ese mice exhibit no anti-DNA antibody in their serum or in kidney eluates, demonstrating that anti-DNA antibodies are not essential for the development of lupus nephritis [61]. Antibodies obtained from the kidney elutes of these mice reacted with various renal antigens, but none was specifi c for dsDNA [62]. Another study eluted Igs from renal tissues obtained from patients with lupus at autopsy and screened the Igs against a panel of 14 diff erent antigens, which included dsDNA, chromatin, Sm, SSA, SSB, and histones [63]. Th ese authors found that only 0.3% to 41.3% of total kidney-eluted IgG reacted with these antigens. Th erefore, a vast majority of renal antibodies bind to yet-unknown antigens. In support of this idea, a study using a glomerular proteome array showed that serum from lupus mice and patients reacts with multiple nuclear and matrix-derived autoantigens [64].

Role of lymphoid cells in lupus nephritis
Lymphoid aggregates with T cells and B cells have been observed within the kidneys affl icted by lupus nephritis, although their intrarenal roles remain to be fully appreciated. T cells also play a major role in pathogenesis of SLE. Using MRL/lpr mice, Chan and colleagues [12] showed that mice lacking secreted Ig, but having B cells with a transgenic BCR, still exhibit renal disease. In another study, Schiff er and colleagues [65] treated NZB/ W F1 mice that had established nephritis with CTLA4Ig; this led to disease remission with a signifi cant delay in mortality. Using a transgenic mouse model system, Heymann and colleagues [66] demonstrated that both cytotoxic T (Tc) cells and Th cells have direct roles in glomerulonephritis. Th e authors used transgenic mice expressing the model antigens ovalbumin and hen egg lysozyme in glomerular epithelial cells called podocytes. Co-injection of ovalbumin-specifi c trans genic CD8 + Tc and CD4 + Th cells into these mice resulted in periglomerular mononuclear infi ltrates and infl ammation of parietal epithelial cells, similar to lesions frequently observed in human chronic glomerulo nephritis. Th e ovalbumin-specifi c CD8 + Tc cells were found to be activated and expanded in the renal lymph nodes, and the activation of T cells in turn could be prevented by depletion of DCs. Crosstalk between tubulointerstitial DCs and Th cells resulted in intrarenal cytokine and chemokine production and in recruitment of more Tc cells, monocyte-derived DCs, and macrophages. Th at study was the fi rst direct evidence that glomerular antigen-specifi c Tc and Th cells can induce glomerulonephritis in a process regulated by DCs. Although similar studies in the context of lupus nephritis are eagerly awaited, the above studies suggest that type IV hypersensitivity-driven mechanisms are likely to be important in mediating autoimmune nephritis.
Kidneys of nephritic NZM2328 mice show high levels of expression of Th 1-type cytokines like IFN-γ and IL-12 [67]. Administration of IFN-γ, a Th 1 cytokine, to NZB/W F1 mice exacerbates disease, whereas the defi ciency of IFN-γ in MRL/lpr mice ameliorates nephritis [32,34]. Similarly, inhibition of IL-18, a cytokine that induces IFN-γ and other Th 1 cytokines, was found to cause a signifi cant reduction in lymphoproliferation and IFN-γ production and resulted in a decrease in lupus nephritis [68]. Th ese studies reinforce the concept that type IV hypersensitivity reactions may also contribute to lupus nephritis.
Other studies have shown a possible role for IL-4, a Th 2-type cytokine, in glomerulosclerosis in which transgenic overexpression of IL-4 was found to facilitate glomerulo sclerosis [69]. In various studies, IL-4 was found to have a direct eff ect on fi broblast proliferation, collagen gene expression, and collagen synthesis [70]. Moreover, inhibition of IL-4 signaling in various lupusprone mouse models was found to protect mice from developing advanced nephritis in the presence of anti-DNA antibody and infi ltrating infl ammatory cells [32]. Th erefore, IL-4 appears to play a pivotal role in the pathogenesis of glomerulosclerosis and chronic renal fi brosis in lupus by acting directly upon resident renal cells.

Role of myeloid cells in lupus nephritis
Infi ltration of DCs in the glomeruli and tubulointerstitial spaces of the kidneys has been reported in various murine models of nephritis, including NZB/W F1 [67], anti-glomerular basement membrane (anti-GBM) [71], and mice engineered to express a foreign antigen on podocytes [66]. DCs may promote lupus nephritis by several mechanisms. One mechanism may be through migration of DCs to local lymph nodes and presentation of renal antigens to autoreactive lymphocytes in the local lymph nodes, thereby initiating an autoimmune response against renal autoantigens [72]. DCs may also secrete a variety of diff erent proinfl ammatory and profi brotic cytokines like IL-6, IL-1, IL-18, IFN-α, tumor necrosis factoralpha (TNF-α), and transforming growth factor-beta to promote renal infl ammation and fi brosis [73]. Despite these possibilities, we do not currently understand the degree to which intrarenal DCs are important for lupus pathogenesis or the exact mechanisms through which they operate.
Similar to DCs, macrophages are recruited to the nephritic kidneys of patients with SLE and lupus-prone mice [74,75] and infl uence the progression of lupus nephritis. In a study using poly(I:C)-induced lupus nephritis in NZB/W mice, proliferative glomerulonephritis was found to be associated with renalinfi ltrating macrophages and renal expression of IFNinducible genes, matrix metalloproteinases (MMPs), and growth factors [76]. Glomerular crescent formation and renal MMP and growth factor expression were dependent on renal macrophages that expressed IL-10, MMPs, osteopontin, and various growth factors, includ ing platelet-derived growth factor-C (PDGF-C) and heparinbinding epidermal growth factor-like growth factor (HB-EGF) [76]. Th ese fi ndings accord a potentially important role for macrophages as mediators of aggressive nephritis in lupus by driving the expression of various cytokines and growth factors in the kidney. Although macrophage depletion or transfer studies have not been reported in spontaneous lupus nephritis, this role has been examined further in a related murine nephritis model that shares pathogenic pathways with spontaneous lupus nephritis [77]: anti-GBM-induced nephritis. In the latter model, depletion and adoptive transfer studies have demonstrated a critical role for macrophages in the pathogenesis of nephritis [78,79].
By implanting renal tubular epithelial cells genetically modifi ed to produce colony-stimulating factor-1 (CSF-1) under the renal capsule of MRL/lpr mice, Kelley and colleagues [80] showed that CSF-1 and TNF-α released by tubular epithelial cells were responsible for promoting renal pathology by fostering macrophage accumulation. In a study using NZB/W lupus-prone mice, Schiff er and colleagues [75] identifi ed an activated type II macrophage population as a key marker for proteinuria onset and disease remission and suggested that therapy for lupus nephritis include strategies that prevent both activation of monocytes and their migration to the kidney.
Neutrophils, another myeloid cell subtype, have also been shown to infi ltrate nephritic kidneys and contribute to the pathogenesis of experimental nephritis [81], although their role in lupus nephritis is less well defi ned. Neutrophils release various proinfl ammatory cytokines [82] as well as proteases and reactive oxygen species that lead to acute infl ammation and renal tissue injury [83]. Further studies in murine models are clearly warranted.

Role of resident renal cells in lupus nephritis
It is clear that many intrinsic renal cells, including podocytes and tubular epithelial cells, have the capacity to costimulate intrarenal T cells via ICAM-I, MHC-II, B-7, and/or CD40-mediated mechanisms [84][85][86] or by releasing pathogenic cytokines [87]. However, the extent to which these intrarenal co-stimulatory mechanisms and cytokines are operative in spontaneous lupus nephritis remains unknown. On the other hand, the notion that intrinsic renal cells could be essential in mediating antibody-mediated nephritis is supported by bone marrow transfer or kidney transplant studies in mice challenged with anti-GBM sera [88][89][90]. Th ese studies have defi ned the roles of MHC-II, INF-α, and Fn14 expression on intrinsic renal cells in mediating nephritis. Overall, we have a very limited understanding of the role that intrinsic renal cells play in spontaneous lupus nephritis.

Conclusions
As discussed in this review, mouse models have proven to be indispensable for understanding the immunological and molecular basis of systemic autoimmunity in lupus.
However, it is becoming increasingly clear that local autoimmunity in target organs and the responses that target organs play are equally important in disease pathogenesis. Murine models are also proving to be instrumental in helping us unravel the intricate mechanisms that underlie the end organ responses in lupus, although the specifi c roles of various cell types warrant systematic investigation. Mouse models have also enhanced our understanding of the respective roles of various cells and molecules in the innate immune system and the interplay between the innate and adaptive immune systems in lupus pathogenesis. Th e challenge ahead is to better defi ne the cellular and molecular players orchestrating lupus and to translate our improved understanding of lupus pathogenesis into better rationalized therapeutics targeting selected cells or molecules (or both) that facilitate lupus.